Earnings Releases·Nov 10, 2026, 7:01 AM ET

Opus Genetics — Third Quarter 2026 Earnings Summary

Net loss widened to $46.5 million ($0.46/share) from $17.5 million ($0.25/share) in Q3 2025, driven by a $19.1 million increase in fair value changes and an $8.1 million rise in R&D expenses, while license revenue fell to $1.1 million from $3.1 million.
Cash reserves increased to $89.0 million as of September 30, 2026, extending the cash runway into 2029, supported by a new note purchase agreement with Oberland Capital Management and a regulatory milestone payment from Viatris Inc.
Key clinical milestones include the initiation of dosing for the OPGx-LCA5 Phase 3 trial in Q4 2026, OPGx-RDH12 Phase 1/2 dosing in Q4 2026, and OPGx-BEST1 Cohort 2 enrollment completion, with top-line data expected in Q1 2027.
The company secured FDA approval for RYZUMVI® for presbyopia, marking its second approved indication, and added Andrew Murphy, Ph.D., as Chief Scientific Officer to support its seven AAV-based pipeline programs.